Gallstone Dissolution Success Rates by Stone Size and Type
- Overview of dissolution therapy
- Success rates by stone size (detailed table)
- Success rates by stone number (solitary vs multiple)
- Success rates by stone composition (cholesterol vs pigment)
- Impact of gallbladder function on success
- Best and worst candidates for dissolution
- Interactive FAQ – 9 common questions
Overview of dissolution therapy
Oral dissolution therapy with ursodeoxycholic acid (UDCA) is the only medical treatment that can dissolve gallstones. However, it is effective only in a minority of patients. Success depends on stone size, number, composition, and gallbladder function. This guide provides evidence‑based success rates to help you understand whether you are a candidate.
Success rates by stone size (detailed table)
Stone diameter is the strongest predictor of dissolution success. Smaller stones dissolve much more reliably.
| Stone diameter (mm) | Complete dissolution rate (12‑24 months) | Typical time to dissolution | Recommendation |
|---|---|---|---|
| <5 mm | 70‑90% | 3‑6 months | Good candidate |
| 5‑10 mm | 40‑60% | 6‑12 months | Moderate candidate – consider |
| 10‑15 mm | 10‑30% | 12‑24 months | Poor candidate – surgery preferred |
| >15 mm | <10% | Often fails | Not recommended – cholecystectomy |
For stones >10mm, the likelihood of complete dissolution is low, and the recurrence rate after stopping UDCA is high. Most guidelines recommend laparoscopic cholecystectomy.
Success rates by stone number (solitary vs multiple)
Multiple stones indicate a more aggressive lithogenic state and are harder to dissolve completely.
- Solitary stone: 50‑70% dissolution rate (depending on size).
- 2‑3 stones: 30‑50%.
- 4 or more stones or stones filling >50% of gallbladder: <20% – UDCA not recommended.
Success rates by stone composition (cholesterol vs pigment)
Stone composition is critical. Only radiolucent, non‑calcified cholesterol stones are dissolvable.
| Stone type | Dissolution rate | Comments |
|---|---|---|
| Pure cholesterol (radiolucent, floating) | 60‑80% | Best candidates |
| Mixed cholesterol (some calcium) | 20‑40% | Poorer response |
| Calcified cholesterol (radiopaque) | 0% | Not suitable |
| Black pigment stones | 0% | Insoluble – surgery needed |
| Brown pigment stones | 0% | Insoluble – ERCP/surgery |
Impact of gallbladder function on success
A functioning gallbladder is essential for dissolution therapy. The gallbladder must contract to empty dissolved cholesterol and small fragments. Non‑functioning gallbladder (e.g., chronic cholecystitis, severe wall thickening, or poor contraction on HIDA scan) leads to failure.
- Normal gallbladder function: 60‑80% dissolution success (for suitable stones).
- Impaired function (ejection fraction <35%): <20% success – UDCA not recommended.
Best and worst candidates for dissolution
Best candidates (70‑90% success):
- Solitary stone <5mm.
- Radiolucent, floating cholesterol stone.
- Normal gallbladder function.
- Normal body weight.
Worst candidates (<20% success):
- Multiple stones or stones >10mm.
- Calcified or pigment stones.
- Non‑functioning gallbladder.
- Obesity or rapid weight loss.
Interactive FAQ – Dissolution success rates
About 50‑60% complete dissolution within 6‑12 months. If no reduction at 12 months, therapy is unlikely to succeed.
Yes, but success rate is lower (30‑50%). Recurrence after stopping UDCA is very high (50‑70% at 5 years).
A plain X‑ray (KUB) shows calcified (radiopaque) stones. Radiolucent stones are not visible – they are candidates for UDCA if other criteria met.
Yes – obese patients have higher cholesterol secretion and lower success rates. Weight loss before therapy may improve outcomes.
Very low (<10%). Laparoscopic cholecystectomy is the appropriate treatment. Do not waste months on UDCA.
Yes – after ESWL fragmentation, UDCA is used to dissolve fragments. Success rates for combined therapy are 60‑80% for select patients.
If no reduction in stone size on ultrasound at 12 months, stop. If stones are smaller but not gone, continue up to 24 months.
Yes – thickened wall (>4mm) suggests chronic cholecystitis and impaired function, reducing dissolution success.
30‑50% at 5 years. Long‑term low‑dose UDCA may reduce recurrence.
Disclaimer: This information is for educational purposes. Consult a gastroenterologist at Vivekananda Hospital to determine if you are a candidate for dissolution therapy.